Financials

v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current Assets    
Cash and cash equivalents $ 27,913,169 $ 19,444,737
Accounts receivable 15,832 7,118
Prepaid expenses 935,498 303,178
Other current assets 527,827 576,660
Total Current Assets 29,392,326 20,331,693
Property and equipment, net 5,266,646 5,171,134
Operating lease right-of-use assets 318,393 326,085
Intangible assets, net 266,586 321,641
Total Assets 35,243,951 26,150,553
Current Liabilities    
Accounts payable 1,083,214 1,539,547
Accrued liabilities 3,152,019 3,491,740
Management and directors' fees payable 91,695 55,174
Current portion of long-term debt 822,369 841,319
Current portion of finance lease liabilities 55,335 59,930
Current portion of operating lease liabilities 157,911 179,624
Current portion of grant repayable 35,554 69,218
Total Current Liabilities 5,398,097 6,236,552
Long-term debt, net of current portion 2,219,748 2,606,885
Finance lease liabilities, net of current portion 557,338 601,967
Operating lease liabilities, net of current portion 166,085 151,828
Grant repayable, net of current portion 273,138 259,603
Total Liabilities 8,614,406 9,856,835
Common Stock    
Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 53,144,082 shares and 48,607,017 shares, respectively 53,144 48,607
Additional paid-in capital 148,468,001 126,526,239
Accumulated other comprehensive income (loss) 29,607 (59,978)
Accumulated deficit (121,817,065) (110,173,971)
Total VolitionRx Limited Stockholders' Equity 26,733,687 16,340,897
Non-controlling interest (104,142) (47,179)
Total Stockholders' Equity 26,629,545 16,293,718
Total Liabilities and Stockholders' Equity $ 35,243,951 $ 26,150,553
v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues        
Royalty $ 0 $ 1,872 $ 0 $ 2,112
Product 24,782 3,322 50,312 3,626
Total Revenues 24,782 5,194 50,312 5,738
Operating Expenses        
Research and development 3,649,469 3,492,845 7,522,547 7,387,811
General and administrative 1,816,599 1,508,836 3,626,759 3,212,358
Sales and marketing 459,371 215,891 886,772 489,845
Total Operating Expenses 5,925,439 5,217,572 12,036,078 11,090,014
Operating Loss (5,900,657) (5,212,378) (11,985,766) (11,084,276)
Other Income (Expenses)        
Grant income 391,532 90,946 391,532 98,870
(Loss) / Gain on disposal of fixed assets (26,166) 93,202 (26,167) 93,202
Interest income 492 7,741 2,213 46,155
Interest expense (39,688) (22,604) (81,869) (56,383)
Total Other Income (Expenses) 326,170 169,285 285,709 181,844
Net Loss (5,574,487) (5,043,093) (11,700,057) (10,902,432)
Net Loss attributable to Non-Controlling Interest 47,539 5,779 56,963 15,346
Net Loss attributable to VolitionRx Limited Stockholders (5,526,948) (5,037,314) (11,643,094) (10,887,086)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments (44,548) (74,320) 89,585 299,606
Net Comprehensive Loss $ (5,619,035) $ (5,117,413) $ (11,610,472) $ (10,602,826)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.10) $ (0.12) $ (0.22) $ (0.26)
Weighted Average Shares Outstanding        
- Basic and Diluted 52,947,173 43,414,318 51,943,534 42,312,172
v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating Activities    
Net loss $ (11,700,057) $ (10,902,432)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 471,754 359,233
Amortization of operating lease right-of-use assets 99,035 125,871
Loss (Gain) on disposal of fixed assets 26,166 (93,202)
Stock-based compensation 893,086 553,309
Common stock issued for Director compensation in Volition Germany 0 333,969
Changes in operating assets and liabilities:    
Prepaid expenses (632,320) (317,795)
Accounts receivable (8,682) (3,223)
Other current assets 50,605 (109,213)
Accounts payable and accrued liabilities (630,236) 959,425
Management and directors' fees payable (36,791) (10,497)
Right-of-use assets operating leases liabilities (98,789) (125,331)
Net Cash Used In Operating Activities (11,566,229) (9,229,886)
Investing Activities:    
Purchases of property and equipment (703,180) (597,366)
Net Cash Used In Investing Activities (703,180) (597,366)
Financing Activities:    
Net proceeds from issuances of common stock 21,183,639 14,234,613
Tax withholdings paid related to stock-based compensation (130,426) 0
Common stock repurchased 0 (54,434)
Proceeds from grants repayable 37,672 3,802
Proceeds from long-term debt 79,614 0
Payments on long-term debt (383,782) (234,172)
Payments on grants repayable (47,830) 0
Payments on finance lease obligations (29,347) (69,483)
Net Cash Provided By Financing Activities 20,709,540 13,880,326
Effect of foreign exchange on cash 28,301 286,024
Net Change in Cash 8,468,432 4,339,098
Cash and cash equivalents - Beginning of Period 19,444,737 16,966,168
Cash and cash equivalents - End of Period 27,913,169 21,305,266
Supplemental Disclosures of Cash Flow Information:    
Interest paid 81,869 56,383
Non-Cash Financing Activities:    
Common stock issued on cashless exercises of stock options 80 20
Offering costs from issuance of common stock $ 119,029 $ 1,229,169
arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus